Liposome encapsulation of ciprofloxacin improves protection against highly virulent francisella tularensis strain schu s4

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3053-3059

  Hamblin, Karleigh A ^a   Armstrong, Stuart J ^a   Barnes, Kay B ^a   Davies, Carwyn ^a   Wong, Jonathan P ^b   Blanchard, James D ^c   Harding, Sarah V ^a   Simpson, Andrew J H ^a   Atkins, Helen S ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^c ARADIGM CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; FLUKA; LIPOSOME; UNCLASSIFIED DRUG; AEROSOL; BACTERIAL VACCINE; LIVE VACCINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; ENCAPSULATION; FEMALE; FRANCISELLA TULARENSIS; LETHALITY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SINGLE DRUG DOSE; TULAREMIA; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LUNG; MICROBIOLOGY; PATHOGENICITY; SURVIVAL ANALYSIS; VIRULENCE;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; AEROSOLS; ANIMALS; BACTERIAL VACCINES; BIOLOGICAL AVAILABILITY; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; FEMALE; FRANCISELLA TULARENSIS; LIPOSOMES; LUNG; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; TULAREMIA; VACCINES, ATTENUATED; VIRULENCE;

EID: 84901246757     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02555-13     Document Type: Article

References (31)

1. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, McDade JE, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K, for the Working Group on Civilian Biodefense. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285:2763-2773. http://dx.doi.org/10.1001/jama.285.21. 2763.
2. Oyston PCF, Sjöstedt A, Titball RW. 2004. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2:967-978. http://dx.doi.org/10.1038/nrmicro1045.
3. Steward J, Piercy T, Lever MS, Simpson AJH, Brooks TJG. 2006. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. Int. J. Antimicrob. Agents 27: 439-443. http://dx.doi.org/10.1016/j.ijantimicag.2006.02.006.
4. Hepburn MJ, Simpson AJH. 2008. Tularemia: current diagnosis and treatment options. Expert Rev. Anti Infect. Ther. 6:231-240. http://dx.doi.org/10.1586/ 14787210.6.2.231.
5. Perez-Castrillon JL, Bachiller-Luque P, Martin-Luquero M, Mena-Martin FJ, Herreros V. 2001. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin. Infect. Dis. 33:573-576. http://dx.doi.org/10.1086/322601.
6. Chocarro A, Gonzalez A, Garcia I. 2000. Treatment of tularemia with ciprofloxacin. Clin. Infect. Dis. 31:623. http://dx.doi.org/10.1086/313946.
7. Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. 2003. Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. North. Am. 17:615-634. http://dx.doi.org/10.1016/S0891-5520 (03)00066-7.
8. Conley J, Yang HM, Wilson T, Blasetti K, Di Ninno V, Schnell G, Wong JP. 1997. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother. 41:1288-1292.
9. Di Ninno VL, Cherwonogrodzky JW, Wong JP. 1993. Liposomeencapsulated ciprofloxacin is effective in the protection and treatment of Balb/c mice against Francisella tularensis. J. Infect. Dis. 168:793-794. http://dx.doi.org/10.1093/infdis/168.3.793.
10. Wong JP, Yang HM, Blasetti KL, Schnell G, Conley J, Schofield LN. 2003. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control Release 92:265-273. http://dx.doi.org/10.1016/S0168- 3659(03)00358-4.
11. Wong JP, Cherwonogrodzky JW, Di Ninno V, Dela Cruz R, Saravolac EG. 1995. Liposome-encapsulated ciprofloxacin for the prevention and treatment of infectious diseases by intracellular pathogens, p 105-120. In Shek PN (ed), Liposomes in biomedical applications. Harwood Academic Press, Amsterdam, The Netherlands.
12. Ahsan F, Rivas IP, Khan MA, Torres Suárez AI. 2002. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control Release 79:29-40. http://dx.doi.org/10.1016/S0168-3659(01)00549-1.
13. Schiffelers R, Storm G, Bakker-Woudenberg I. 2001. Liposomeencapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 48:333-344. http://dx.doi.org/10.1093/jac/48.3.333.
14. Bruinenberg P, Blanchard J, Cipolla D, Dayton F, Mudumba S, Gonda I. 2010. Inhaled liposomal ciprofloxacin: once a day management of respiratory infections. In Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (ed), Respiratory Drug Delivery 2010, vol 1, p 73-82. Virginia Commonwealth University, Richmond, VA.
15. Serisier D. 2012. Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin. Drugs Today 48:339-351. http://dx.doi.org/ 10.1358/dot.2012.48.5.1789474.
16. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I. 2013. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 68:812-817. http://dx.doi.org/10. 1136/thoraxjnl-2013-203207.
17. Hartley G, Taylor R, Prior J, Newstead S, Hitchen PG, Morris HR, Dell A, Titball RW. 2006. Grey variants of the live vaccine strain of Francisella tularensis lack lipopolysaccharide O-Antigen, show reduced ability to survive in macrophages and do not induce protective immunity in mice. Vaccine 24:989-996. http://dx.doi.org/10.1016/j.vaccine.2005.08.075.
18. Druett HA. 1969. A mobile form of the Henderson apparatus. Epidemiol. Infect. 67:437-448.
19. Harper GJ, Morton JD. 1953. The respiratory retention of bacterial aerosols: experiments with radioactive spores. Epidemiol. Infect. 51:372-385.
20. Guyton AC. 1947. Measurement of the respiratory volumes of laboratory animals. Am. J. Physiol. 150:70-77.
21. Rowland M, Tozer TN. 2010. Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th ed, p 159-215. Lippincott Williams and Wilkins, Philadelphia, PA.
22. Oyeka ICA, Ebuh GU, Nwosu CR. 2012. Analysis of tied data: an alternative non-parametric approach. Int. J. Eng. Sci. Technol. 4:811-817.
23. Piercy T, Steward J, Lever MS, Brooks TJG. 2005. In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice. J. Antimicrob. Chemother. 56:1069-1073. http://dx.doi.org/10.1093/jac/dki359.
24. Eigelsbach HT, Downs CM. 1961. Prophylactic effectiveness of live and killed tularemia vaccines. J. Immunol. 87:415-425.
25. Kadzhaev K, Zingmark C, Golovliov I, Bolanowski M, Shen H, Conlan W, Sjöstedt A. 2009. Identification of genes contributing to the virulence of Francisella tularensis SCHU S4 in a mouse intradermal infection model. PLoS One 4:e5463. http://dx.doi.org/10.1371/journal.pone.0005463.
26. Eigelsbach HT, Braun W, Herring RD. 1951. Studies on the variation of Bacterium tularense. J. Bacteriol. 61:557-569.
27. Brain JD, Knudson DE, Sorokin SP, Davis MA. 1976. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ. Res. 11:13-33. http://dx.doi.org/10.1016/0013-9351(76) 90107-9.
28. Oh YK, Nix DE, Straubinger RM. 1995. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob. Agents Chemother. 39:2104-2111. http://dx.doi.org/10.1128/AAC.39.9.2104.
29. Brechner R, DiFerdinando G, Bresntiz E, Factor SH, Matte TD, Siegel L, Adams S, Walks I, Davies-Coles J, Richardson M, Peterson E, Stroube R. 2001. Update: adverse events associated with anthrax prophylaxis among postal employees-New Jersey, New York City, and the District of Columbia Metropolitan Area, 2001. JAMA 286:2935-2936. http://dx.doi.org/10.1001/jama.286.23.2935.
30. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K, for the Working Group on Civilian Biodefense. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287: 2236-2252. http://dx.doi.org/10.1001/jama.287.17.2236.
31. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K, for the Working Group on Civilian Biodefense. 2000. Plague as a biological weapon: medical and public health management. JAMA 283:2281-2290. http://dx.doi.org/10. 1001/jama.283.17.2281.